Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density, published as a randomized controlled trial.

The background data of these two groups were identical.

Who Took Part

The study group was 241 patients.

PubMed tags the participants as women only.

A total of 241 osteoporotic patients were enrolled in a 24-month randomized open label study.

Serum level of Glu-osteocalcin (Glu-OC) and menaquinone-4 levels were measured at the end of the follow-up period.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Serum level of OC and urinary excretion of deoxypyridinoline (DPD) were measured before and after the treatment.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Amino Acids, Biomarkers, Bone Density, Bone Remodeling, Fractures, Spontaneous and Incidence.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 241 patients in people with osteoporosis and bone density.

The publication is from 2000 (Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.